Real-Life Considerations on Antifungal Treatment Combinations for the Management of Invasive Mold Infections after Allogeneic Cell Transplantation
暂无分享,去创建一个
F. Giannotti | C. van Delden | Y. Chalandon | S. Masouridi-Levrat | D. Neofytos | E. Glampedakis | A. Mamez | R. Roth
[1] F. Giannotti,et al. Invasive Mold Infections in Allogeneic Hematopoietic Cell Transplant Recipients in 2020: Have We Made Enough Progress? , 2021, Open forum infectious diseases.
[2] M. Hoenigl,et al. All You Need to Know and More about the Diagnosis and Management of Rare Mold Infections , 2021, mBio.
[3] P. Le Pape,et al. Invasive aspergillosis due to Aspergillus section Usti: a multicenter retrospective study. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[4] J. Perfect,et al. Combination Therapy for Invasive Fungal Infections , 2020, Current Fungal Infection Reports.
[5] J. Perfect,et al. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[6] H. Badali,et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. , 2019, The Lancet. Infectious diseases.
[7] N. Mueller,et al. Incidence and outcome of invasive fungal diseases after allogeneic hematopoietic stem cell transplantation: A Swiss transplant cohort study , 2018, Transplant infectious disease : an official journal of the Transplantation Society.
[8] C. Beigelman-Aubry,et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. , 2018, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[9] D. Kontoyiannis,et al. Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[10] D. Denning,et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[11] L. Pagano,et al. Combination antifungal therapy for invasive mould diseases in haematologic patients. An update on clinical data , 2015, Journal of chemotherapy.
[12] I. Raad,et al. Invasive aspergillosis caused by Aspergillus terreus: an emerging opportunistic infection with poor outcome independent of azole therapy. , 2014, The Journal of antimicrobial chemotherapy.
[13] T. Walsh,et al. In Vitro Combination of Isavuconazole with Micafungin or Amphotericin B Deoxycholate against Medically Important Molds , 2014, Antimicrobial Agents and Chemotherapy.
[14] P. Chiusolo,et al. Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[15] R. Fanin,et al. Multicentre surveillance study on feasibility, safety and efficacy of antifungal combination therapy for proven or probable invasive fungal diseases in haematological patients: the SEIFEM real‐life combo study , 2013, Mycoses.
[16] B. Spellberg,et al. Combination therapy for mucormycosis: why, what, and how? , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[17] D. Kontoyiannis,et al. How I treat mucormycosis. , 2011, Blood.
[18] Thomas J Walsh,et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[19] E. Anaissie,et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[20] K. Marr,et al. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[21] J. Perfect,et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[22] R. Goldberg,et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[23] C. Heussel,et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[24] M. Boeckh,et al. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[25] Raoul Herbrecht,et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[26] R. Barbó,et al. Combination Antifungal Therapy for Invasive Aspergillosis , 2005 .
[27] M. Boeckh,et al. Combination antifungal therapy for invasive aspergillosis. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[28] Russell E. Lewis,et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies , 2003, Cancer.
[29] A. Polak,et al. Fungistatic and Fungicidal Effects of Amphotericin B, Ketoconazole and Fluconazole (UK 49, 858) against Histoplasma capsulatum in vitro and in vivo , 1987, Mykosen.
[30] A. Schaffner,et al. The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis. , 1985, The Journal of infectious diseases.